🇺🇸 FDA
Patent

US 10899732

Substituted benzamides useful as sodium channel blockers

granted A61KA61K31/416A61P

Quick answer

US patent 10899732 (Substituted benzamides useful as sodium channel blockers) held by Xenon Pharmaceuticals Inc. expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Xenon Pharmaceuticals Inc.
Grant date
Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/416, A61P, A61P11/00, A61P17/04